A legislation was signed today banning transgender minors from receiving gender-affirming care in Tennessee by Gov. Bill Lee. The bill prohibits the minors from receiving altering surgeries and hormone treatments.
A legislation was signed today banning transgender minors from receiving gender-affirming care in Tennessee by Gov. Bill Lee. The bill prohibits the minors from receiving altering surgeries and hormone treatments.
Lee also signed a second law restricting drag shows from taking place in public or in front of children.
Tennessee is just another state where lawmakers introduced legislation attacking gender-affirming medical care for young people, although these services have been available in the U.S. for more than a decade.
Outside of surgeries, the legislation signed by Lee bans medications such as puberty blockers and hormone treatments to treat any underlying gender dysphoria cause. This will affect minors 18 and under who identify as transgender and nonbinary.
However, minors who receive these services prior to July 1, 2023 can continue to be treated by doctors until March 31, 2024. Minors who have not received this specific care may not do so after the July date.
According to CBS, Democratic Rep. Gloria Johnson referenced Tennessee's abortion ban that went into affect last year, before Thursday's legislation was voted on.
"We have taken away a woman's right to determine her health care and her health outcomes — and now we've gone to children," she said. "If a doctor and a family feels that taking hormone blockers is going to be healthy and productive and life-saving for these children, that's a decision that should be made."
Other civil organizations such as Lambda Legal, the American Civil Liberties Union, and the ACLU of Tennessee, who are against the legislation shared their thoughts on the decision in a joint response.
“We will not allow this dangerous law to stand. Certain politicians and Governor Lee have made no secret of their intent to discriminate against youth who are transgender or their willful ignorance about the life-saving health care they seek to ban," they said. "Instead, they’ve chosen fearmongering, misrepresentations, intimidation and extremist politics over the rights of families and the lives of transgender youth in Tennessee.
We are dedicated to overturning this unconstitutional law and are confident the state will find itself completely incapable of defending it in court. We want transgender youth to know they are not alone and this fight is not over.”
AstraZeneca, Daiichi Sankyo Submit New BLA for Datopotamab in Lung Cancer
November 12th 2024After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for datopotamab deruxtecan for patients with advanced or metastatic nonsquamous non-small cell lung cancer.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Breast Cancer Patients Desire Early, Frequent Financial Screening
November 11th 2024Current financial screening procedures in the United States may need to change, according to recent research done by Laila Gharzai, M.D., LLM, from the Department of Radiation Oncology at Northwestern University.
Read More
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
The Takeaway From Study of Midlife MS Patients: Don't Stop Disease-Modifying Therapy
Published: November 11th 2024 | Updated: November 11th 2024People with multiple sclerosis (MS) often stop taking disease-modifying therapy as they transition from relapsing-remitting MS to secondary progressive MS. This study shows that people who stop stop disease-modifying therapy have higher hospitalization rates and more visits to the emergency room.
Read More